Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor
- PMID: 1388162
Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor
Abstract
A tetradecapeptide corresponding to the P1 to P14 region of the reactive-bond loop of antithrombin (AT) binds to the inhibitor, presumably as a middle strand of the A beta-sheet, thereby converting AT from an inhibitor to a substrate of thrombin (Björk, I., Ylinenjärvi, K., Olson, S.T., and Bock, P. E. (1992) J. Biol. Chem. 267, 1976-1982). The kinetics of cleavage of the AT reactive bond in the AT-peptide complex by four target proteinases were quantified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and densitometry. The kcat/Km values for thrombin and factor IXa were indistinguishable from the second-order rate constants for AT inhibition of these enzymes, whereas the values for factor Xa and plasmin were 10-17-fold higher than the inhibition rate constants. Heparin with high affinity for AT accelerated the substrate reaction with thrombin to an extent consistent with the reduced heparin affinity of the AT-peptide complex. These data show that blocking by the peptide of the putative intramolecular association of the P1 to P14 region of the AT reactive-bond loop with the A beta-sheet leads to AT functioning as a substrate of its target enzymes with an efficiency that equals or exceeds the action of uncomplexed AT as an inhibitor and with the expected heparin activation. The results thus suggest that a substrate-like attack of the proteinase on the inhibitor reactive bond in an exposed loop initiates the inhibition reaction. This attack presumably induces the subsequent trapping of the enzyme by the insertion of the reactive-bond loop into the A beta-sheet.
Similar articles
-
Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor.J Biol Chem. 1992 Jan 25;267(3):1976-82. J Biol Chem. 1992. PMID: 1730729
-
Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A beta-sheet of the inhibitor during trapping of target proteinases.Biochemistry. 1993 Jul 6;32(26):6501-5. doi: 10.1021/bi00077a002. Biochemistry. 1993. PMID: 7687144
-
The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.Biochemistry. 2001 Jun 5;40(22):6670-9. doi: 10.1021/bi002933d. Biochemistry. 2001. PMID: 11380262
-
Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.Fed Proc. 1985 Feb;44(2):404-9. Fed Proc. 1985. PMID: 3155697 Review.
-
Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition.J Enzyme Inhib. 1995;9(1):3-15. doi: 10.3109/14756369509040677. J Enzyme Inhib. 1995. PMID: 8568565 Review.
Cited by
-
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.Am J Pathol. 2002 Dec;161(6):2053-63. doi: 10.1016/S0002-9440(10)64484-7. Am J Pathol. 2002. PMID: 12466122 Free PMC article.
-
Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization.J Cell Mol Med. 2009 Aug;13(8B):2304-2316. doi: 10.1111/j.1582-4934.2008.00608.x. J Cell Mol Med. 2009. PMID: 19120695 Free PMC article.
-
Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin.Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):499-504. doi: 10.1073/pnas.95.2.499. Proc Natl Acad Sci U S A. 1998. PMID: 9435220 Free PMC article.
-
Probing serpin reactive-loop conformations by proteolytic cleavage.Biochem J. 1996 Mar 1;314 ( Pt 2)(Pt 2):647-53. doi: 10.1042/bj3140647. Biochem J. 1996. PMID: 8670081 Free PMC article.
-
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 33415130 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials